RFX6单倍剂量不足通过损害β细胞功能易感糖尿病
研究利用CRISPR构建等基因多能干细胞模型(人胚胎干细胞与患者来源干细胞),分化为胰岛谱系并植入免疫缺陷小鼠。纯合RFX6-/-模型不能生成分泌胰岛素的β细胞;杂合RFX6+/-胰岛RFX6蛋白表达降低54.2%,钙信号改变、胰岛素分泌在基础和高糖条件下分别降低62%和54%,但β细胞数量和胰岛素含量不受影响,该分泌缺陷在体内植入后持续存在。
要点
- 纯合RFX6-/-干细胞模型不能生成分泌胰岛素的β细胞,伴前体标志物NEUROG3和SOX9上调及凋亡增加。
- 杂合RFX6+/-胰岛RFX6蛋白表达降低54.2%,β细胞成熟标志物降低、钙信号改变。
- 杂合RFX6+/-胰岛基础和高糖条件下胰岛素分泌分别降低62%和54%,β细胞数量和胰岛素含量无影响。
核心结论
- RFX6单倍剂量不足不影响β细胞数量或胰岛素含量,但损害β细胞功能,使功能缺失变异杂合携带者易感糖尿病。
研究设计与样本
- 研究使用CRISPR技术构建等基因多能干细胞模型,包括人胚胎干细胞模型和患者来源干细胞模型,分化为干细胞来源胰岛(SC-islets)后植入免疫缺陷NOD-SCID-Gamma小鼠。
主要发现
- 纯合RFX6-/-干细胞模型未能生成分泌胰岛素的胰腺β细胞,重现Mitchell-Riley综合征表型。
- 胰腺内分泌阶段前体标志物NEUROG3和SOX9上调,伴随凋亡增加。
- 杂合RFX6+/- SC-islets显示RFX6单倍剂量不足,蛋白表达降低54.2%,β细胞成熟标志物降低、钙信号改变。
- 杂合RFX6+/- SC-islets在基础和高糖条件下胰岛素分泌分别降低62%和54%,β细胞数量和胰岛素含量无影响。
- 胰岛素分泌降低在小鼠体内植入后持续存在。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Regulatory factor X 6 (RFX6) is crucial for pancreatic endocrine development and differentiation. The RFX6 variant p.His293LeufsTer7 is significantly enriched in the Finnish population, with almost 1:250 individuals as a carrier. Importantly, the FinnGen study indicates a high predisposition for heterozygous carriers to develop type 2 and gestational diabetes. However, the precise mechanism of this predisposition remains unknown. METHODS: To understand the role of this variant in beta cell development and function, we used CRISPR technology to generate allelic series of pluripotent stem cells. We created two isogenic stem cell models: a human embryonic stem cell model; and a patient-derived stem cell model. Both were differentiated into pancreatic islet lineages (stem-cell-derived islets, SC-islets), followed by implantation in immunocompromised NOD-SCID-Gamma mice. RESULTS: Stem cell models of the homozygous variant RFX6-/- predictably failed to generate insulin-secreting pancreatic beta cells, mirroring the phenotype observed in Mitchell-Riley syndrome. Notably, at the pancreatic endocrine stage, there was an upregulation of precursor markers NEUROG3 and SOX9, accompanied by increased apoptosis. Intriguingly, heterozygous RFX6+/- SC-islets exhibited RFX6 haploinsufficiency (54.2% reduction in protein expression), associated with reduced beta cell maturation markers, altered calcium signalling and impaired insulin secretion (62% and 54% reduction in basal and high glucose conditions, respectively). However, RFX6 haploinsufficiency did not have an impact on beta cell number or insulin content. The reduced insulin secretion persisted after in vivo implantation in mice, aligning with the increased risk of variant carriers to develop diabetes. CONCLUSIONS/INTERPRETATION: Our allelic series isogenic SC-islet models represent a powerful tool to elucidate specific aetiologies of diabetes in humans, enabling the sensitive detection of aberrations in both beta cell development and function. We highlight the critical role of RFX6 in augmenting and maintaining the pancreatic progenitor pool, with an endocrine roadblock and increased cell death upon its loss. We demonstrate that RFX6 haploinsufficiency does not affect beta cell number or insulin content but does impair function, predisposing heterozygous carriers of loss-of-function variants to diabetes. DATA AVAILABILITY: Ultra-deep bulk RNA-seq data for pancreatic differentiation stages 3, 5 and 7 of H1 RFX6 genotypes are deposited in the Gene Expression Omnibus database with accession code GSE234289. Original western blot images are deposited at Mendeley ( https://data.mendeley.com/datasets/g75drr3mgw/2 ).
引用
- Ibrahim H, Balboa D, Saarimäki-Vire J, et al. RFX6 haploinsufficiency predisposes to diabetes through impaired beta cell function. Diabetologia. 2024. PMID: 38743124. doi:10.1007/s00125-024-06163-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。